Bnan

عضوة في جسفت للفنون التشكيلية

[أيمن الغامدي @Aimantoon]

معادلة ذهبية | للفيديو الناجح :
▪️ Hook (جذاب)
▪️قيمة وفائدة
▪️دعوة للتفاعل
من برنامج #صباح_الخير_يا_عرب

[أيمن الغامدي @Aimantoon]

من دورة #الذكاء_الاصطناعي
في الإعلام الجديد

[مجمع إرادة والصحة النفسية بالدمام @E1ACMH]

قوتك الحقيقية أن تقول : لا
| #قرارك_يحميك
#اليوم_العالمي_لمكافحة_المخدرات
مجمع إرادة والصحة النفسية بـ #الدمام أحد مكونات #تجمع_الشرقية_الصحي

[Bnan @nooobel]

@bassambinabbas يارب يارب يارحيم
كيف دكتور يحصل عليه ولدي الدكتور يقول هو في المرحلة الثالثة

طمنا

[أ.د. بسام صالح بن عباس @bassambinabbas]

https://t.co/Wv5BP7VfyA

[Breakthrough T1D UK @BT1DUK]

Today, history has been made: NICE has approved teplizumab for use on the NHS in England and Wales.

Teplizumab is the first ever immunotherapy that can delay the onset of type 1 diabetes symptoms for people in the early stages of the condition.

For the first time, we’re not just managing type 1 - we’re changing its course.

This milestone means many things. But above all, it means time.

More time to simply be a child. A reduction in emergency diagnoses and serious complications like diabetic ketoacidosis. A softer landing for individuals and families suddenly facing management of a life-long condition, and with it, renewed hope for the future.

And this achievement belongs to you, our community. Breakthrough T1D funded early-stage research and the clinical trials that made teplizumab a reality. This breakthrough was made possible by your belief and support.

Together, we are changing what’s possible. 💙

Read the full story here: https://t.co/SpC7qZPoAq

#GBDoc #Type1Diabetes #Teplizumab

[Bnan @nooobel]

@alyaum @Aimantoon ماشاءالله شي مبشر بفضل الله ثم الغرامات وساهر

[صحيفة اليوم @alyaum]

سجلت السعودية انخفاضًا تاريخيًا في وفيات الحوادث المرورية بأكثر من 60% خلال الفترة من 2016 إلى 2025. وتصدرت المنطقة الشرقية مناطق المملكة في معايير العناية بالشأن المروري، تلتها الجوف ثم جازان.
#اليوم
التفاصيل: https://t.co/H9IpxCg8b0

[Breakthrough T1D @BreakthroughT1D]

The best minds. The boldest ideas. One amazing event.

Join us October 9–11 in Philadelphia, PA for the inaugural Breakthrough T1D Clinical & Research Congress!

This landmark event is where researchers, healthcare professionals, and people living with T1D come together to share the latest data, best practices, and breakthroughs shaping the future of T1D.

Register today at https://t.co/fGaIyGSuKb

[Breakthrough T1D @BreakthroughT1D]

Great news! Senate Diabetes Caucus co-chairs @SenatorShaheen and @SenatorCollins have sent a letter to Acting FDA Commissioner Diamantas urging the reclassification of deceased donor islets as organs.
Momentum is building. These islets can help some people living with T1D today.

The regulatory pathway needs to catch up, and Breakthrough T1D will keep pushing until it does.

Thank you to our champions in the Senate! Use your voice: https://t.co/fsHfD6cTo5

[Breakthrough T1D @BreakthroughT1D]

Today marks a historic milestone for the type 1 diabetes (T1D) community: the @US_FDA has approved Tzield for use in individuals ages 8–17 with stage 3 T1D. This is the first disease-modifying therapy ever approved for stage 3 T1D!

Tzield preserves beta cell function in newly diagnosed individuals, which has been shown to result in fewer hypoglycemic events, lower insulin use, reduced burden of care, and improved A1c. We'll keep working to ensure people with stage 3 T1D everywhere, not just in the U.S., have access to therapies that help them live healthier lives.

Breakthrough T1D and the T1D Fund have supported the development of this therapy for over 30 years, and we're grateful to the FDA for recognizing the urgent unmet need in T1D and expediting Tzield's approval through the accelerated approval pathway. We also thank @sanofi for their continued research and the T1D community for advocating for therapies that change the course of this disease. Read more here: https://t.co/OaU1VQV1cZ

[Bnan @nooobel]

@T1Mommy متى تصل لنا

[Bnan @nooobel]

@T1Mommy اين اجده في السعوديةً

[Bnan @nooobel]

@T1Mommy بشرونا هل اقدر احصل عليه من المستشفى

[Breakthrough T1D @BreakthroughT1D]

Lynn Starr, Breakthrough T1D’s Chief Global Advocacy Officer, speaks about how critical advocacy work is to helping move type 1 diabetes (T1D) research progress forward, and the pivotal role that data plays in our advocacy efforts.

Be sure to join us on Wednesday, June 10 at 6 pm ET across our social channels for a mid-year mission update where you’ll be able to hear about all the incredible progress being made!

[Breakthrough T1D @BreakthroughT1D]

Breakthrough T1D CEO Dr. Aaron Kowalski shares some of the exciting type 1 diabetes (T1D) research he's looking forward to hearing about at #ADA2026!

Be sure to stay tuned for more coverage, and join us on June 10 at 6pm ET for a mid-year mission update!

You can tune in across our social media channels--you won't want to miss it!

[Bnan @nooobel]

@aLoNeDarkEns @Sernovabio @AmDiabetesAssn We are all with you, called upon to overcome this suffering. How can we know the results? ♥️🙏

[Bnan @nooobel]

@Sernovabio @AmDiabetesAssn good ♥️🙏

[Sernova @Sernovabio]

This #WomensHealthMonth, we are recognizing how #Type1Diabetes impacts women differently. These differences highlight the need for personalized, adaptable treatments, reflecting our mission to an approach for all people living with #T1D. Learn more: https://t.co/GdjwQH3drq

[Bnan @nooobel]

@Sernovabio @AmDiabetesAssn Thank you, we are waiting for you every day, every minute, every second.